MA50900A - Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations - Google Patents

Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations

Info

Publication number
MA50900A
MA50900A MA050900A MA50900A MA50900A MA 50900 A MA50900 A MA 50900A MA 050900 A MA050900 A MA 050900A MA 50900 A MA50900 A MA 50900A MA 50900 A MA50900 A MA 50900A
Authority
MA
Morocco
Prior art keywords
transcrit
ilt3
specific antibodies
immunoglobulin type
immunoglobulin
Prior art date
Application number
MA050900A
Other languages
English (en)
Inventor
Philip E Brandish
Laurence Fayadat-Dilman
Veronica Juan
Michael A Meehl
Carl Mieczkowski
Latika Singh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA50900A publication Critical patent/MA50900A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050900A 2017-11-17 2018-11-15 Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations MA50900A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762587604P 2017-11-17 2017-11-17

Publications (1)

Publication Number Publication Date
MA50900A true MA50900A (fr) 2020-09-23

Family

ID=64572590

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050900A MA50900A (fr) 2017-11-17 2018-11-15 Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations

Country Status (26)

Country Link
US (6) US11111297B2 (fr)
EP (1) EP3710479A2 (fr)
JP (1) JP7194481B2 (fr)
KR (1) KR102478433B1 (fr)
CN (2) CN111712518B (fr)
AR (1) AR113696A1 (fr)
AU (1) AU2018367524B2 (fr)
BR (1) BR112020009759A8 (fr)
CA (1) CA3082409A1 (fr)
CL (1) CL2020001240A1 (fr)
CO (1) CO2020006405A2 (fr)
CR (1) CR20200204A (fr)
DO (1) DOP2020000074A (fr)
EA (1) EA202091228A1 (fr)
EC (1) ECSP20032082A (fr)
GE (2) GEP20237565B (fr)
IL (1) IL274574A (fr)
JO (1) JOP20200131A1 (fr)
MA (1) MA50900A (fr)
MX (2) MX2020005128A (fr)
NI (1) NI202000036A (fr)
PE (1) PE20210475A1 (fr)
PH (1) PH12020550890A1 (fr)
SG (1) SG11202004426SA (fr)
TW (1) TWI816715B (fr)
WO (1) WO2019099597A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
MA50900A (fr) * 2017-11-17 2020-09-23 Merck Sharp & Dohme Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
WO2021127200A1 (fr) * 2019-12-19 2021-06-24 Ngm Biopharmaceuticals, Inc. Agents de liaison à ilt3 et leurs méthodes d'utilisation
CA3181197A1 (fr) 2020-05-01 2021-11-04 NGM Biopharmaceuticals, Inc Agents de liaison a ilt et leurs methodes d'utilisation
KR20230158057A (ko) * 2021-03-19 2023-11-17 머크 샤프 앤드 돔 엘엘씨 항-ilt3 항체를 사용하여 암을 치료하는 방법
AU2022318734A1 (en) * 2021-07-28 2024-02-08 Merck Sharp & Dohme Llc Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
CN116082502A (zh) * 2021-11-08 2023-05-09 复旦大学 Galectin8与LILRB4结合的调节剂及其应用
WO2023140875A1 (fr) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Utilisations d'agents de liaison ilt3
US20250206820A1 (en) 2022-03-29 2025-06-26 Ngm Biopharmaceuticals, Inc. Ilt3 and cd3 binding agents and methods of use thereof
AU2023258644A1 (en) 2022-04-25 2024-12-05 Biond Biologics Ltd. Anti-ilt3 antibodies and use thereof
WO2023235699A1 (fr) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Anticorps dirigés contre lilrb4 et leurs utilisations
CN114716553B (zh) * 2022-06-08 2022-08-23 北京科诺信诚科技有限公司 靶向人lilrb4的纳米抗体及其应用
CN119894934A (zh) 2023-05-18 2025-04-25 南京维立志博生物科技股份有限公司 结合lilrb4和cd3的抗体及其用途
WO2025062392A1 (fr) 2023-09-20 2025-03-27 Biond Biologics Ltd. Combinaisons de blocage anti-ilt3
WO2025141589A1 (fr) 2023-12-31 2025-07-03 Biond Biologics Ltd. Traitement du cancer à l'aide d'anticorps anti-ilt3

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0042924B1 (fr) 1980-06-30 1984-03-21 International Business Machines Corporation Appareil de transfert de données
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
CA2352572C (fr) 1998-12-01 2010-04-20 Abbvie Biotherapeutics Inc. Anticorps anti-interferon gamma humanises
AU2002345878A1 (en) * 2001-06-25 2003-01-08 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2391438A1 (fr) 2002-05-01 2003-11-01 Procyon Biopharma Inc. Reactifs et methodes diagnostiques a base de psp94
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US8207110B2 (en) * 2004-09-03 2012-06-26 The Trustees Of Columbia University In The City Of New York ITL3 polypeptides and uses thereof
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EP1907001B1 (fr) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Molecules de liaison ilt3 et leurs utilisations
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
MX2008007682A (es) * 2005-12-20 2008-10-23 Sbi Biotech Co Ltd Anticuerpo anti-ilt7.
WO2007089945A2 (fr) 2006-02-02 2007-08-09 The Trustees Of Columbia University In The City Of New York Méthodes de traitement de maladies par ciblage du ilt3
CA2655903A1 (fr) 2006-06-19 2008-08-07 Tolerx, Inc. Molecules se liant a l'ilt3 et leurs utilisations
GB0705775D0 (en) 2007-03-26 2007-05-02 Affitech As Product
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ， エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
EP2242773B1 (fr) 2008-02-11 2017-06-14 Cure Tech Ltd. Anticorps monoclonaux pour le traitement de tumeurs
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
EP2328920A2 (fr) 2008-08-25 2011-06-08 Amplimmune, Inc. Polypeptides co-stimulateurs ciblés et leurs procédés d'utilisation dans le traitement du cancer
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
CN101830978A (zh) * 2009-03-09 2010-09-15 中国科学院微生物研究所 一种人免疫球蛋白样受体突变体及其应用
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
MX341925B (es) 2010-03-29 2016-09-07 Zymeworks Inc Anticuerpos con funcion efectora suprimida o mejorada.
NZ602515A (en) 2010-04-16 2015-06-26 Transbio Ltd Proteins that bind pi16 and uses thereof
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
WO2014116846A2 (fr) 2013-01-23 2014-07-31 Abbvie, Inc. Procédés et compositions pour moduler une réponse immunitaire
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
IL283834B (en) 2014-09-28 2022-07-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016127427A1 (fr) 2015-02-15 2016-08-18 华为技术有限公司 Procédé de traitement pour boîtier de dispositif électronique, boîtier de dispositif électronique et dispositif électronique
AU2016229201B2 (en) 2015-03-06 2021-01-28 The Board Of Regents Of The University Of Texas System Anti-LILRB antibodies and their use in detecting and treating cancer
EP3325006A4 (fr) 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York Procédés de traitement du cancer exprimant cd166
SG11201804178YA (en) 2015-11-18 2018-06-28 Merck Sharp & Dohme Pd1 and/or lag3 binders
SG10202101958YA (en) 2016-08-31 2021-03-30 Agency Science Tech & Res Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof
EP3538141A4 (fr) 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. Ligand ilt3
MA47468A (fr) 2017-02-09 2019-12-18 Bluefin Biomedicine Inc Anticorps anti-ilt3 et conjugués anticorps-médicament
MA50900A (fr) * 2017-11-17 2020-09-23 Merck Sharp & Dohme Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
KR20230158057A (ko) * 2021-03-19 2023-11-17 머크 샤프 앤드 돔 엘엘씨 항-ilt3 항체를 사용하여 암을 치료하는 방법
AU2022318734A1 (en) * 2021-07-28 2024-02-08 Merck Sharp & Dohme Llc Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
JP2024532762A (ja) * 2021-08-11 2024-09-10 オンコホスト リミテッド 患者応答の予測
WO2023159152A2 (fr) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Polythérapie d'un antagoniste de lilrb et d'un inhibiteur d'axe pd -1/pd-l1
WO2023235699A1 (fr) * 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Anticorps dirigés contre lilrb4 et leurs utilisations
US20260042835A1 (en) * 2022-07-28 2026-02-12 Merck Sharp & Dohme Llc Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies

Also Published As

Publication number Publication date
CN120058946A (zh) 2025-05-30
TWI816715B (zh) 2023-10-01
GEAP202315366A (en) 2023-07-25
US20190153093A1 (en) 2019-05-23
MX2025000940A (es) 2025-03-07
KR102478433B1 (ko) 2022-12-15
MX2020005128A (es) 2020-07-27
ECSP20032082A (es) 2020-08-31
BR112020009759A8 (pt) 2023-01-31
AU2018367524A1 (en) 2020-06-11
TW201922786A (zh) 2019-06-16
KR20200083598A (ko) 2020-07-08
EP3710479A2 (fr) 2020-09-23
US12441792B2 (en) 2025-10-14
EA202091228A1 (ru) 2020-08-12
AR113696A1 (es) 2020-06-03
US20220010010A1 (en) 2022-01-13
US11111297B2 (en) 2021-09-07
US20220033497A1 (en) 2022-02-03
CN111712518B (zh) 2025-03-25
US20220025043A1 (en) 2022-01-27
DOP2020000074A (es) 2020-08-31
CO2020006405A2 (es) 2020-06-09
GEP20237565B (en) 2023-11-10
JOP20200131A1 (ar) 2020-05-28
WO2019099597A3 (fr) 2019-06-13
IL274574A (en) 2020-06-30
US20220010011A1 (en) 2022-01-13
AU2018367524B2 (en) 2022-09-15
JP2021503280A (ja) 2021-02-12
BR112020009759A2 (pt) 2020-11-03
US20220025042A1 (en) 2022-01-27
JP7194481B2 (ja) 2022-12-22
NI202000036A (es) 2020-09-24
CR20200204A (es) 2020-06-18
CL2020001240A1 (es) 2020-12-18
SG11202004426SA (en) 2020-06-29
PE20210475A1 (es) 2021-03-08
CA3082409A1 (fr) 2019-05-23
US12435133B2 (en) 2025-10-07
CN111712518A (zh) 2020-09-25
PH12020550890A1 (en) 2021-04-12
WO2019099597A2 (fr) 2019-05-23

Similar Documents

Publication Publication Date Title
MA50900A (fr) Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
FR25C1029I1 (fr) Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations
EP3411071A4 (fr) Nouveaux anticorps monoclonaux anti-cd 47 et leurs utilisations
FR26C1002I1 (fr) Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
MA54539A (fr) Anticorps anti-muc16 x anti-cd28 bispécifiques et leurs utilisations
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
EP3891183A4 (fr) Anticorps anti-claudine et leurs utilisations
EP3759143A4 (fr) Anticorps anti-tigit et leurs utilisations
EP3621642A4 (fr) Anticorps monoclonaux humains contre lag3 et leurs utilisations
MA52970A (fr) Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations
MA54540A (fr) Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
EP3898691A4 (fr) Anticorps trem2 et leurs utilisations
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA52949A (fr) Anticorps anti-pd-1 et leurs utilisations
EP3426686A4 (fr) Anticorps anti-pacap humanisés et leurs utilisations
EP3846850A4 (fr) Anticorps humanisés anti-c5 et leurs utilisations
EP3790586A4 (fr) Anticorps anti-dll3 et leurs utilisations
EP3833693A4 (fr) Anticorps bispécifiques anti-pd-l1/anti-lag3 et leurs utilisations
EP3661555A4 (fr) Anticorps bispécifiques et leurs utilisations
EP3966252A4 (fr) Anticorps anti-cd137 humanisés et leurs utilisations
EP3850012A4 (fr) Anticorps anti-tnfrsf9 et leurs utilisations
EP3755714A4 (fr) Anticorps anti-angiopoïétine-2 et leurs utilisations
MA54469A (fr) Anticorps anti-il-27 et leurs utilisations
EP3755716A4 (fr) Anticorps anti-pd-1 et leurs utilisations
MA52235A (fr) Anticorps anti-phf-tau et leurs utilisations